Dr. Roth's research focuses on studying disease mechanisms in lymphoma and developing novel therapeutic strategies. her work has identified novel genomic alterations in HIV-related lymphomas (Giulino et al, Blood 2011), Burkitt lymphoma (Giulino-Roth et al, Blood 2012), and Hodgkin lymphoma (Reichel et al, Blood 2015, plenary paper). This work led her to explore more basic mechanisms of disease and therapies targeted at these mechanisms including targeting stress signaling in Burkitt lymphoma (Giulino-Roth et al, Mol Cancer Ther, 2017), epigenetic dysregulation in diffuse large B-cell lymphoma (Scholze et al, Blood Advances 2020), and viral immunogenicity in EBV+ lymphomas (Dalton et al, Blood 2020, Guo et al, Nature Microbiology 2020). Dr. Roth's laboratory research is highly translational and linked to her clinical research where she is conducting clinical trials in lymphoma in both pediatric and adult patients. She is study chair for two trials within the Children’s Oncology Group: a phase II trial evaluating pembrolizumab in pediatric Hodgkin lymphoma (COG AHOD1822) and a phase III trial evaluating nivolumab in primary mediastinal B-cell lymphoma (COG ANHL1931). This work has been recognized with awards from the NIH (R37 MERIT Award 2022), the American Society of Clinical Investigation (Young Physician Scientist Award 2021), the American Society of Hematology (ASH Scholar Award 2021), and Hyundai Hope on Wheels (Young Investigator Award 2015, Scholar Hope Award, 2021).